VEGFA and glaucoma: The disruption of NO signalling pathways, particularly through endothelial NOS, by anti-VEGF agents may lead to a decrease in NO levels below physiological baseline, which is thought to be a key mechanism in the development of glaucoma and other processes [20,33,37].